Karyopharm Therapeutics Net Worth
Karyopharm Therapeutics Net Worth Breakdown | KPTI |
Karyopharm Therapeutics Net Worth Analysis
Karyopharm Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Karyopharm Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Karyopharm Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Karyopharm Therapeutics' net worth analysis. One common approach is to calculate Karyopharm Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Karyopharm Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Karyopharm Therapeutics' net worth. This approach calculates the present value of Karyopharm Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Karyopharm Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Karyopharm Therapeutics' net worth. This involves comparing Karyopharm Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Karyopharm Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Karyopharm Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Karyopharm Therapeutics' net worth research are outlined below:
| Karyopharm Therapeutics had very high historical volatility over the last 90 days | |
| Karyopharm Therapeutics has some characteristics of a very speculative penny stock | |
| Karyopharm Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 146.03 M. Net Loss for the year was (143.1 M) with profit before overhead, payroll, taxes, and interest of 151.86 M. | |
| Karyopharm Therapeutics currently holds about 170.85 M in cash with (92.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Karyopharm Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Cutaneous T-cell Lymphoma Market Landscape Report 2024 Comprehensive Insights About 25 Companies and 30 Pipeline Drugs |
Karyopharm Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Karyopharm Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Karyopharm Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Karyopharm Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Karyopharm Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Karyopharm Therapeutics backward and forwards among themselves. Karyopharm Therapeutics' institutional investor refers to the entity that pools money to purchase Karyopharm Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Gsa Capital Partners Llp | 2024-09-30 | 1.8 M | Jane Street Group Llc | 2024-06-30 | 1.5 M | Cam Group Holding A/s | 2024-06-30 | 1.5 M | Opaleye Management Inc | 2024-06-30 | 1.4 M | Geode Capital Management, Llc | 2024-06-30 | 1.3 M | Jpmorgan Chase & Co | 2024-06-30 | 1.3 M | Deutsche Bank Ag | 2024-06-30 | 1.3 M | Renaissance Technologies Corp | 2024-09-30 | 1.2 M | Kennedy Capital Management Inc | 2024-06-30 | 1.2 M | Vanguard Group Inc | 2024-09-30 | 7.7 M | Eversept Partners, Llc | 2024-09-30 | 5.5 M |
Follow Karyopharm Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 105.89 M.Market Cap |
|
Project Karyopharm Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.62) | |
| Return On Capital Employed | (0.76) | (0.72) | |
| Return On Assets | (0.60) | (0.62) | |
| Return On Equity | 1.05 | 1.10 |
When accessing Karyopharm Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Karyopharm Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Karyopharm Therapeutics' profitability and make more informed investment decisions.
Evaluate Karyopharm Therapeutics' management efficiency
Karyopharm Therapeutics has return on total asset (ROA) of (0.3427) % which means that it has lost $0.3427 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9105) %, meaning that it created substantial loss on money invested by shareholders. Karyopharm Therapeutics' management efficiency ratios could be used to measure how well Karyopharm Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The Karyopharm Therapeutics' current Return On Equity is estimated to increase to 1.10, while Return On Tangible Assets are projected to decrease to (0.62). The Karyopharm Therapeutics' current Asset Turnover is estimated to increase to 0.64, while Total Assets are projected to decrease to under 238.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.19) | (1.13) | |
| Tangible Book Value Per Share | (1.19) | (1.13) | |
| Enterprise Value Over EBITDA | (1.89) | (1.98) | |
| Price Book Value Ratio | (0.73) | (0.69) | |
| Enterprise Value Multiple | (1.89) | (1.98) | |
| Price Fair Value | (0.73) | (0.69) | |
| Enterprise Value | 1.1 B | 1.1 B |
Understanding the operational decisions made by Karyopharm Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 1.1225 | Revenue 148.4 M | Quarterly Revenue Growth 0.077 | Revenue Per Share 1.247 | Return On Equity (8.91) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Karyopharm Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Karyopharm Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Karyopharm Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Karyopharm Therapeutics time-series forecasting models is one of many Karyopharm Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Karyopharm Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Karyopharm Therapeutics Earnings per Share Projection vs Actual
Karyopharm Therapeutics Corporate Management
| Reshma MD | Chief VP | Profile | |
| James JD | Chief Officer | Profile | |
| Sohanya MBA | Executive Officer | Profile | |
| Cameron Peters | Principal Financial Officer, Principal Accounting Officer | Profile | |
| Sharon MBA | CoFounder Board | Profile | |
| Mr MS | VP Affairs | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 1.247 | Quarterly Revenue Growth 0.077 | Return On Assets (0.34) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.